The ESRF ID23-2 beam line is a microfocus beam line fully dedicated for studying macromolecular microcrystals. It is a fixed wavelength beam line using a single bounce Si[111] monochromator; the beam is focused down to 7.5 µm horizontally by 5 µm vertically (FWHM) by Pt-coated silicon mirrors in a Kirkpatrick-Baez (KB) geometry. The experimental setup is composed of a MD2m diffractometer (from MAATEL, under an EMBL patent), a SC3 sample changer [1] and a MarMOSAIC 225 CCD detector. The main challenge for ID23-2 was to provide to the MX user community a beam line with a beam size smaller than 10 µm in diameter while keeping the same "easy-to-use" environment and reliability as the other ESRF MX beam lines (ID14, ID23-1, ID29, BM14) [2] . The beam line has been open to the user community since mid-November 2005. The first year of user operation has demonstrated that the design was basically sound and that the beamline can be used by inexperienced users. Instrumentation developments, data collection strategies and some user results will be presented and discussed. Cypovirus and baculovirus are two unrelated types of insect virus that both produce very unusual infective particles -stable micron sized protein crystals called polyhedra that can remain infective in soil for years. Polyhedra form inside infected larval cells and consist of a body centred cubic lattice of 28kD viral polyhedrin protein molecules. How the growing crystals selectively incorporate virus particles from the complex intracellular 'soup' is intriguing. Cypovirus polyhedra form in the cytoplasm and baculovirus polyhedra form in the nucleus. The amino acid sequences of the corresponding polyhedrin molecules have no evident homology. Despite these differences the unit cells of the two polyhedra have nearly identical 103Å cell dimensions. Polyhedra are unusually stable and easily obtained protein crystals and may in future provide an interesting platform for protein engineering. We are interested in these possibilities and in understanding the structural biology of these unique viral structures. Using samples provided mainly by Hajime Mori at the Kyoto Institute of Technology, we have been collecting micro-beam X-ray diffraction data from viral polyhedra since 2004 in collaboration with Clemens Schulze-Briese at the Swiss Light Source. The ~2Å resolution atomic structure of cypovirus was obtained in 2006 using MIR methods. The talk will summarise the project.
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A new beamline to achieve protein microcrystallography at SPring-8 BL32XU, a new undulator beamline at SPring-8 for protein microcrystallography, is being under construction and will be operated for the National Project from 2010 in Japan. Recently, users' demands for high-quality data collection from protein microcrystals are increasing as target proteins get large and difficult to be crystallized. Achieving the objective requires very high signalto-noise ration of diffraction spots from a sample crystal. Spatially brilliant and small beam, of the order of a few or several micrometers, is proved to achieve the objective at several synchrotron radiation facilities. We designed a micro-focus beamline, BL32XU at SPring-8, which provides dense and micro-sized X-rays. A hybrid in-vacuum undulator developed at SPring-8 will be equipped. X-rays C36 from the device is monochromatized with liquid-N2 cooled double crystal monochromator, and will be focused by using K-B mirrors fabricated with Elastic Emission Machinery. Ray trace calculation with the designed configurations shows achievable beam size at sample position corresponds to 1 x 2 µm 2 with 10 10 phtons/sec. Beam size is designed to be changeable from about 1~25 µm 2 according to designed experiments. The new beamline will largely benefits users by cutting off their wasting time to optimize crystallization conditions especially for smaller and lower quality crystals. The beamline will provide high quality diffraction datasets from micro crystals. Besides, users will be able to probe single-crystal volumes from a heterogeneous protein crystal using the micro-beam. Designed optics and instrumentations to be equipped such as an automated sample changer, advanced software to avoid serious radiation damages and so on will be also presented. The I24 microfocus macromolecular crystallography beamline at the Diamond Light Source comes into operation in 2008. The beamline is tuneable from 6.5 -25 keV and offers versatility in beam size and shape at both sample position and detector position by utlizing a two-stage demagnification incorporating a movable final Kirkpatrick-Baez mirror pair. The beamline incorporates a CATS sample mounting robot that will also enable diffraction screening of crystallization conditions in 96 well plates. This facility will provide invaluable feedback for the crystallization efforts in the Wellcome Trust funded Membrane Protein Laboratory at Diamond. Significant design and build effort has been put into versatility, stability and the generation of a low background sample environment for the measurement of diffraction data. The design concepts of I24 will be described and preliminary results from beamline commissioning will be presented. Fragment-based screening is a powerful method for the identification of attractive chemistry start points against specific drug targets. These initial low molecular weight fragment hits typically have uM to mM potency but are shown to be highly ligand efficient. Astex Therapeutics uses its proprietary platform, PyramidTM, utilising high-throughput X-ray crystallography and other biophysical techniques, to identify high quality fragment hits against a broad range of therapeutic targets. The availability of structural information from the screening phase provides a detailed map of the active and secondary fragment binding sites allowing the chemist to design molecules that maximise interaction with the protein target. Rapid progress can be achieving reducing the time taken to identify a clinical candidate by many years. To highlight the success of our approach, AT7519 (a CDK inhibitor) and AT9283 (Aurora inhibitor), which are both currently in Phase I clinical trials will be discussed together with another non-kinase oncology target, HSP90.
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